This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Catalyst (CPRX) Skyrockets 110% Over a Year: Here's Why
by Zacks Equity Research
Catalyst's (CPRX) stock price has more than doubled in the past year, driven by its sole marketed drug, Firdapse, approved for the treatment of Lambert-Eaton Myasthenic Syndrome in adults.
Catalyst Pharmaceutical (CPRX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Catalyst (CPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) Q4 Earnings Lag Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -16.67% and 8.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study
by Zacks Equity Research
The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.
Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales
by Zacks Equity Research
Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics
by Zacks Equity Research
Catalyst Pharmaceuticals, Chinook Therapeutics, Assertio Holdings and Sigilon Therapeutics have been highlighted in this Industry Outlook article.
JAZZ Q4 Earnings Top, Sales Ride on New & Acquired Drugs
by Zacks Equity Research
JAZZ's product revenues grow in the fourth quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
4 Small Drug Stocks That Appear to Be Solid Bets in a Challenging Industry
by Kinjel Shah
Some business disruption due to COVID-19 was felt by the Medical-Drugs industry players in 2021. CPRX, KDNY, ASRT and SGTX may prove to be good additions to one's portfolio.
Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4
by Zacks Equity Research
Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.
Wall Street Analysts Predict a 25% Upside in Catalyst (CPRX): Here's What You Should Know
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 25.2% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What Makes Catalyst (CPRX) a Good Fit for "Trend Investing"
by Zacks Equity Research
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y
by Zacks Equity Research
Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.
Emergent's (EBS) Q4 Earnings & Sales Beat, CDMO View Cut
by Zacks Equity Research
Emergent's (EBS) fourth-quarter 2021 earnings and sales beat estimates. The company lowers its guidance for 2022 CDMO services revenues and adjusted net income.
Allogene (ALLO) Beats on Q4 Earnings, Resumes Clinical Studies
by Zacks Equity Research
Allogene (ALLO) beats earnings estimates for the fourth quarter. However, the stock declines in after-market trading. All clinical studies have been resumed following the removal of clinical hold last month.
Esperion (ESPR) Q4 Earnings Beat, Product Sales Rise 49%
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports solid fourth-quarter results, beating estimates for earnings and sales. Stock surges.
Y-mAbs (YMAB) Stock Up on Pre-BLA Meeting Completion With FDA
by Zacks Equity Research
Following a pre-BLA meeting with the FDA, Y-mAbs Therapeutics (YMAB) expects to resubmit its filing for omburtamabin CNS/leptomeningeal metastases from neuroblastoma by the end of first-quarter 2022.
Here's Why Momentum in Catalyst (CPRX) Should Keep going
by Zacks Equity Research
Catalyst (CPRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Wall Street Analysts See a 33% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 33.3% upside potential for Catalyst (CPRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Is Aravive (ARAV) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aravive (ARAV) and Catalyst Pharmaceutical (CPRX) have performed compared to their sector so far this year.
Catalyst's (CPRX) Stock Up on 2022 Guidance for Firdapse
by Zacks Equity Research
Catalyst Pharmaceuticals (CPRX) reports preliminary sales figures for the fourth quarter. The company also provides its revenue guidance for 2022.
ChemoCentryx (CCXI) Gets Positive CHMP Opinion for Tavneos
by Zacks Equity Research
ChemoCentryx (CCXI) receives a positive recommendation from the CHMP for its lead drug Tavneos to treat two forms of ANCA-associated vasculitis.
How Much Upside is Left in Catalyst (CPRX)? Wall Street Analysts Think 30%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.6% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Catalyst's (CPRX) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Catalyst's (CPRX) earnings meet estimates in the third quarter of 2021 while revenues beat the same.
Jazz Pharma (JAZZ) Q3 Earnings Beat, New Drugs Drive Sales
by Zacks Equity Research
Jazz Pharma's (JAZZ) product revenues grow in the third quarter on the back of strong demand for its new drugs and drugs added with the acquisition of GW Pharmaceuticals.
Catalyst Pharmaceutical (CPRX) Q3 Earnings Meet Estimates
by Zacks Equity Research
Catalyst (CPRX) delivered earnings and revenue surprises of 0.00% and 4.30%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?